TIDMREDX

RNS Number : 9673M

Redx Pharma plc

27 September 2021

REDX PHARMA PLC

("Redx" or "the Company")

Exercise of Options and Total Voting Rights

Alderley Park, 27 September 2021, Redx Pharma plc (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, announces the exercise of share options by a former employee of the Company over 500,000 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") at exercise prices of 22 pence (166,666 shares), 33 pence (166,667 shares) and 50 pence (166,667 shares) per share respectively.

Application has been made to the London Stock Exchange for the 500,000 new Ordinary Shares to be admitted to trading on AIM and admission is expected to occur on or around 8.00am on 28 September 2021. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue.

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following the above issue of equity, the issued share capital of the Company will comprise 275,282,205 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.

 
For further information, please contact: 
 
Redx Pharma Plc                              T: +44 1625 469 918 
Peter Presland, Interim Chairman 
 Lisa Anson, Chief Executive 
 Peter Collum, Chief Financial Officer 
 
SPARK Advisory Partners (Nominated Adviser)   T: +44 203 368 3550 
Matt Davis/Adam Dawes 
 
WG Partners LLP (Joint Broker)               T: +44 20 3705 9330 
Claes Spång/ David Wilson 
 
Panmure Gordon (UK) Limited (Joint Broker)   T: +44 20 7886 2500 
Rupert Dearden/Freddy Crossley/Emma Earl 
 
FTI Consulting                               T: +44 20 3727 1000 
Simon Conway/Ciara Martin 
 

About Redx Pharma Plc

Redx Pharma (AIM:REDX) is focused on the discovery and development of novel targeted medicines for the treatment of cancer and fibrotic diseases, aiming initially to progress them to clinical proof of concept, before evaluating options for further development and potential value creation. Redx's lead oncology asset, the Porcupine inhibitor RXC004, is expected to commence a Phase 2 programme in H2 2021. The Company's selective ROCK2 inhibitor, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical study in June 2021 for which results are expected in 2022.

The Company has a strong track record of discovering new drug candidates through its core capability of converting medicinal chemistry insights into differentiated and commercially attractive drug candidates, with five proprietary or partnered assets in late pre-clinical or clinical development. One of those assets, a BTK inhibitor - pirtobrutinib/LOXO-305 - was sold to Loxo Oncology (now Eli Lilly) and is currently in Phase 3 clinical studies in chronic lymphocytic leukaemia. In addition, Redx has forged pre-clinical asset partnerships with other blue chip companies including AstraZeneca and Jazz Pharmaceuticals.

To subscribe to Email Alerts from Redx, please visit: www.redxpharma.com/investor-centre/email-alerts/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCPPURGBUPGGQC

(END) Dow Jones Newswires

September 27, 2021 02:59 ET (06:59 GMT)

Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024 Haga Click aquí para más Gráficas Redx Pharma.
Redx Pharma (LSE:REDX)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024 Haga Click aquí para más Gráficas Redx Pharma.